Bay 43-9006, a dual-action inhibitor, targets the RAF/MEK/ERK signaling pathway in tumor cells, and receptor tyrosine kinases VEGFR/PDGFR in tumor vasculature [102]. The gene discussed is PDGFRB; the disease is neoplasm.